Story perspectives

Mosliciguat Phase 2 results cut pulmonary resistance 56.3%

9/9/2026

Summary

Story summary

Roivant Sciences reported mosliciguat cut pulmonary vascular resistance by 56.3% in a Phase 2 trial.
The trial met its primary endpoint at Week 16, showing a placebo-adjusted reduction versus a 6.6% increase.
Patients receiving mosliciguat walked 35.2 meters farther and had a 357.7 pg/mL NT-proBNP drop versus placebo.
Cough occurred in 12.1% of treated patients compared with 18.2% on placebo.
Roivant launched the Phase 3 PHrontier trial to further evaluate mosliciguat in PH-ILD.

1 of 1

Story summary

Roivant Sciences reported mosliciguat cut pulmonary vascular resistance by 56.3% in a Phase 2 trial.
The trial met its primary endpoint at Week 16, showing a placebo-adjusted reduction versus a 6.6% increase.
Patients receiving mosliciguat walked 35.2 meters farther and had a 357.7 pg/mL NT-proBNP drop versus placebo.
Cough occurred in 12.1% of treated patients compared with 18.2% on placebo.
Roivant launched the Phase 3 PHrontier trial to further evaluate mosliciguat in PH-ILD.